直肠癌患者血清3种肿瘤标志物联合检测的临床意义

目的探讨肿瘤标志物组织多肽抗原(TPA)、糖类抗原242(CA242)和癌胚抗原(CEA)在直肠癌诊断和疗效观察中的应用价值。方法应用酶联免疫吸附试验(ELISA)测定40例健康对照组及57例直肠癌患者血清TPA、CA242和CEA水平,并对32例直肠癌患者进行术后随访检测。结果直肠癌患者TPA、CA242和CEA水平及检测阳性率均高于健康对照组,差异有统计学意义(P0.05),3种肿瘤标志物联合检测对直肠癌的阳性检出率明显升高;直肠癌患者经有效治疗后其血清3种肿瘤标志物水平显著降低,差异有统计学意义(P0.05)。结论TPA、CA242和CEA3种肿瘤标志物联合检测对直肠癌的诊断及术后疗效观察有重要意义。

The clinical value of measurement of serum TPA,CA242 and CEA in patients with rectum cancer

Objective To investigate the clinical application of serum tumor marker tissue polypeptide-specific antigen（TPA） ,carbohydrate antigen（CA242） and carcinoembryonic antigen （CEA） in diagnosis and monitoring for rectum cancer. Methods The serum level of TPA,CA242 and CEA was detected by enzymelinked immunosorbent assay（ELISA） for the patients（57 cases） with rectum cancer and 40 healthy controls. The three tumor marker levels of 32 patients with rectum cancer were determined after surgery treatment to judge the prognostic value. Results The serum levels and the positive rate of TPA ,CA242 and CEA were higher in the rectum cancer group than those in healthy people with a high statistical significance （P〈0.05） ,and after surgery treatment the three tumor marker levels of 32 patients were decreased with a high statistical sigificance （P〈0. 05 ）. Conclusion The combined assay of TPA ,CA242 and CEA might be of high value for the early diagnosis and monitoring of rectum cancer.